Results 1 to 10 of about 82,112 (180)

Antifungal Drug Repurposing [PDF]

Antibiotics, 2020
Control of fungal pathogens is increasingly problematic due to the limited number of effective drugs available for antifungal therapy. Conventional antifungal drugs could also trigger human cytotoxicity associated with the kidneys and liver, including ...
Jong H. Kim, Luisa W. Cheng, Kathleen L. Chan, Christina C. Tam, Noreen Mahoney, Mendel Friedman, Mikhail Martchenko Shilman, Kirkwood M. Land   +7 more
doaj   +3 more sources

Drug Repurposing as an Effective Drug Discovery Strategy: A Critical Review [PDF]

Drug Design, Development and Therapy
Abdulaziz H Al Khzem,1 Saad M Wali2 1Department of Pharmaceutical Chemistry, College of Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, 31441, Eastern Province, Kingdom of Saudi Arabia; 2Pharmacology and Toxicology Department, College of ...
Al Khzem AH, Wali SM
doaj   +2 more sources

Rare Disease Drug Repurposing.

JAMA Netw Open
ImportanceTreatments are urgently needed for the more than 9500 rare diseases with no US Food and Drug Administration–approved therapies. Although repurposing can be less time- and cost-intensive compared with novel drug development, hurdles have impeded systematic repurposing.
Nijim S, Korsunska A, Zinski J, Bolden SE, Zuccato M, Repasky M, Fajgenbaum DC.   +6 more
europepmc   +3 more sources

Editorial: Drug Repurposing [PDF]

Frontiers in Medicine, 2019
Pan Pantziarka, Pan Pantziarka, Pan Pantziarka, Nicolas André, Nicolas André, Nicolas André   +5 more
doaj   +4 more sources

Does collective consciousness compromise during epidemics and pandemics? [PDF]

EAI Endorsed Transactions on Smart Cities, 2021
The ongoing pandemic, COVID-19, has received unprecedented global attention. Though a pathogen is essentially the causative agent, the dynamics of the cause-effect in major events like the ongoing COVID-19 pandemic is not ...
Anoushka Khanna, Namita I, Rina Chakrabarti, Prem Indraganti   +3 more
doaj   +1 more source

Paclitaxel and Therapeutic Drug Monitoring with Microsampling in Clinical Practice

Pharmaceuticals, 2023
Paclitaxel is an anticancer agent efficacious in various tumors. There is large interindividual variability in drug plasma concentrations resulting in a wide variability in observed toxicity in patients.
Mirjana Radovanovic, Peter Galettis, Alex Flynn, Jennifer H. Martin, Jennifer J. Schneider   +4 more
doaj   +1 more source

Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment

Cells, 2022
Glioblastoma is a highly aggressive, invasive and treatment-resistant tumour. The DNA damage response (DDR) provides tumour cells with enhanced ability to activate cell cycle arrest and repair treatment-induced DNA damage.
Mathew Lozinski, Nikola A. Bowden, Moira C. Graves, Michael Fay, Bryan W. Day, Brett W. Stringer, Paul A. Tooney   +6 more
doaj   +1 more source

A Path to Real-World Evidence in Critical Care Using Open-Source Data Harmonization Tools

Critical Care Explorations, 2023
COVID-19 highlighted the need for use of real-world data (RWD) in critical care as a near real-time resource for clinical, research, and policy efforts.
Smith F. Heavner, PhD, RN, Wesley Anderson, PhD, Rahul Kashyap, MBBS, MBA, Pamela Dasher, BA, Ewy A. Mathé, PhD, Laura Merson, Philippe J. Guerin, MD, PhD, Jeff Weaver, MBA, Matthew Robinson, MD, Marco Schito, PhD, Vishakha K. Kumar, MD, MBA, Paul Nagy, PhD   +11 more
doaj   +1 more source

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy

BMC Cancer, 2022
Background Platinum chemoresistance results in high-grade serous ovarian cancer (HGSOC) disease recurrence. Recent treatment advances using checkpoint inhibitor immunotherapy has not benefited platinum-resistant HGSOC.
Michelle W. Wong-Brown, Andre van der Westhuizen, Nikola A. Bowden   +2 more
doaj   +1 more source

Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers

Pharmacology Research & Perspectives, 2021
Trial data support an absence of an exposure–survival relationship for pembrolizumab. As these relationships remain unexamined in a real‐world setting, we determined them in metastatic melanoma prospectively in an observational study.
Vishal Navani, Moira C. Graves, Giovana Celli Marchett, Hiren Mandaliya, Nikola A. Bowden, Andre van derWesthuizen   +5 more
doaj   +1 more source